Plus Therapeutics Inc

PSTV

0.212USD

-0.018-7.87%

Market hours （ET）Quotes delayed by 15 min

Plus Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

117 / 391

Overall Ranking

233 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Plus Therapeutics Inc Highlights

StrengthsRisks

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.

Growing

The company is in a growing phase, with the latest annual income totaling USD 5.21M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 5.21M.

Undervalued

The company’s latest PE is -0.80, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 5.42M shares, increasing 20.50% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.28M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.28.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

5.700

Target Price

+2246.64%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Plus Therapeutics Inc is 8.10, ranking 51 out of 391 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 1.37M, representing a year-over-year decrease of 3.19%, while its net profit experienced a year-over-year decrease of 46.37%.

Score

Industry at a Glance

Previous score

8.10

Change

0



Financials

7.50

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.36

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.30

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.36

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Plus Therapeutics Inc is 8.04, ranking 68 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.80, which is -90.37% below the recent high of -0.08 and -28.13% above the recent low of -1.02.

Score

Industry at a Glance

Previous score

8.04

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 117/391

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Plus Therapeutics Inc is 8.00, ranking 163 out of 391 in the Biotechnology & Medical Research industry. The average price target is 4.00, with a high of 21.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

8.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Plus Therapeutics Inc is 4.73, ranking 338 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.30 and the support level at 0.19, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.77

Change

-0.04

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Plus Therapeutics Inc is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 2.94%, representing a quarter-over-quarter decrease of 59.08%. The largest institutional shareholder is The Vanguard, holding a total of 2.28M shares, representing 1.33% of shares outstanding, with 594.20% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

1.45M

+4346.17%

BlackRock Institutional Trust Company, N.A.

469.39K

+6644.09%

S.H.N. Financial Investments Ltd

1.50M

+69.40%

Geode Capital Management, L.L.C.

813.25K

+1489.12%

UBS Financial Services, Inc.

623.87K

+611.88%

State Street Investment Management (US)

341.89K

--



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Plus Therapeutics Inc is 2.81, ranking 193 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.85. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Plus Therapeutics Inc

PSTV

6.36 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Madrigal Pharmaceuticals Inc

MDGL

8.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Day One Biopharmaceuticals Inc

DAWN

8.26 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.21 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment